A look at causes, symptoms, and care options for neuromuscular diseases, and how we're leading the way to better treatments and cures.
MDA Grants $7 Million in New Research Funding
Following the unprecedented approval of three drugs in six months to treat neuromuscular diseases, we're pushing for more progress with $7 million in new research funding.
Eteplirsen Granted Accelerated Approval
The FDA has granted accelerated approval to eteplirsen for the treatment of Duchenne muscular dystrophy! Decades of MDA research and investment have paid off with the first disease-modifying drug available to treat DMD.
Phase 2 clinical trial will test Vamorolone in boys with DMD
A $3 Million NIH Grant follows early MDA support for experimental “dissociative steroid.”
May is ALS Awareness Month
With our collective strength, we will support families in hometowns across America and help everyone with ALS live longer, stronger lives.
Meet Zane
“Wild and crazy” Zane Jacobs is determined to live life unlimited despite the challenges of DMD.
Marathon Pharmaceuticals expands DMD patient access to Deflazacort.
Medical centers across the country are now participating in open-label expanded access program (EAP) called ACCESS DMD
Read MDA News to stay up-to-date on issues that matter to the MDA community.
Biomarkers can provide crucial information for researchers conducting clinical trials.
James Ervasti, professor in the department of biochemistry, molecular biology & biophysics at the University of Minnesota in Minneapolis, is working to develop methods of identifying non-invasive biomarkers.
The FDA has approved Taro Pharmaceuticals’ Keveyis 50 mg tablets for primary hyperkalemic and hypokalemic periodic paralysis.
MDA helps you keep up on research news, health care information and helpful daily living strategies through magazines, print and online publications, educational speakers, seminars, videos and newsletters.
The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization.
©2017, Muscular Dystrophy Association Inc. All rights reserved.
